Retinal Vein Occlusion Market: Global Industry Analysis and Forecast (2023-2029)

Retinal Vein Occlusion Market size was valued at US$ 13.90 Bn. in 2022 and the total revenue is expected to grow at 10.7 % through 2022 to 2029, reaching nearly US$ 28.33 Bn.
Retinal Vein Occlusion Market Overview:
A blood clot stops the vein in the retina, causing retinal vein occlusion. It can happen when the veins in the eyes are too narrow. It is more common in persons who have diabetes, as well as those who have high blood pressure, high cholesterol, or other health issues that influence blood flow. The signs and symptoms of retinal vein blockage range from mild to severe. There is no pain associated with the blurring or loss of eyesight. Almost always, it just affects one eye. The blurring or loss of vision may be minor at first but gradually worsens over the next few hours or days. Occasionally, full visual loss occurs nearly instantly.To know about the Research Methodology :- Request Free Sample Report
Retinal Vein Occlusion Market Dynamics:
The key factors affecting the growth of the market are the rising prevalence of Patients with lymphoma, glaucoma, and myeloma, and growing the rate of atherosclerosis and diabetes. Other factors include lifestyle changes, an increase in the prevalence of eye diseases, and technological discoveries. All of the disorders mentioned above are vascular and ophthalmic. Retinal vascular dysfunction is a disease that affects the blood vessels of the eye and causes visual impairment or vision loss. This disease can be treated with a Focal laser and an anti-VEGF injection.

Retinal occlusion is a type of ophthalmic condition in which a blood clot plugs the vein of the eye because the veins are too small. Anti-VEGF injections prevent the growth of new blood vessels in the eye, which can lead to glaucoma. The global rise in ophthalmic disease, as well as an increase in the elderly population with eye disease, are projected to have an impact on the growth of the global Retinal Vein Occlusion Market. The high cost of treatment and drug side effects are some of the worldwide Retinal Vein Occlusion Market's restraints.

Moreover, technological investment by the market players in the field of treatment and diagnosis is likely to boost the growth of the market. Further, market players are investing a huge amount in product development and expansion of product portfolios. These factors are likely to boost the growth of the market in the forecast period.
Retinal Vein Occlusion Market Segment Analysis:
The Central retinal vein occlusion segment is dominating the Type segment of the Retinal Vein Occlusion Market:

In 2022, the market was led by central retinal vein occlusion, and this trend is expected to continue over the forecast period. The development of therapeutics for Central Retinal Vein Occlusion involves several major companies. The introduction of new therapeutics will have a substantial impact on the Central Retinal Vein Occlusion industry. A greater understanding of disease pathophysiology will aid in the development of new Central Retinal Vein Occlusion therapies. The development of causal-based therapy is justified due to CRVO remains a reasonably common cause of mainly unilateral visual loss. Prevalence rates in population-based research range from 0.1-0.5 %, with the middle and older age groups being the most affected. The prevalence of CRVO has been estimated to be 0.8 per 1000 (confidence interval 0.61–0.99) based on data from individual population-based research. The prevalence of the disease rises with age and is unaffected by gender or race/ethnicity.

The Anti-VEGF segment is considered to supplement the growth of the Retinal Vein Occlusion Market.

In 2022, the anti-VEGF medicines category accounted for the majority of the global retinal vein occlusion market. The segment is driven by an increase in the prevalence and incidence of diabetes. Anti-VEGF medications are used to treat a variety of eye disorders that produce new blood vessel growth or swelling under the macular portion of your retina, which is located at the back of your eyes.

The macula is a small part of the central retina that is critical for perceiving detail, color, and objects in front of you. When abnormal blood vessel growth or swelling occurs in the macula, it can interfere with central detailed vision and functions such as reading, watching television, or recognizing faces. Anti-VEGF therapy is started as soon as possible before the new blood vessels or swelling cause too much harm to the macula. Hence, the Anti-VEGF segment is estimated to gain the largest market share in the forecast period.
Retinal Vein Occlusion Market Regional Insights:
The Asia Pacific is likely to boost the growth of the Retinal Vein Occlusion Market.

The Asia Pacific is likely to dominate the growth of market expansion owing to a growth in the senior population, which is prone to chronic ophthalmic disorders, the Asia Pacific region is estimated as the fastest-growing segment throughout the projected period. However, as healthcare infrastructure improves and people become more aware of ocular disorders, this factor is further estimated to lift the market. Dominating countries of Asia Pacific are China, India, Japan, Nepal, Indonesia, and various others. Nepal's high prevalence of cardiovascular and other systemic disorders is fueling the market for retinal vein occlusion. Laser photocoagulation and intravitreal injections of either VEGF inhibitors or steroids are being promoted as treatment possibilities. When compared to macular laser photocoagulation or intravitreal injections of triamcinolone, intravitreal injections of VEGF inhibitors for RVO result in good visual and anatomic outcomes.

The objective of the report is to present a comprehensive analysis of the Retinal Vein Occlusion Market to the stakeholders in the industry. The past and current status of the industry with the forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that include market leaders, followers, and new entrants.

PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors of the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers.

The report also helps in understanding the Retinal Vein Occlusion Market dynamics, structure by analyzing the market segments and project the Retinal Vein Occlusion Market size. Clear representation of competitive analysis of key players by Grade, price, financial position, Grade portfolio, growth strategies, and regional presence in the Retinal Vein Occlusion Market make the report investor’s guide.
Retinal Vein Occlusion Market Scope: Inquire before buying



Global Retinal Vein Occlusion Market


Report Coverage
Details


Base Year:
2022
Forecast Period:
2023-2029


Historical Data:
2018 to 2022
Market Size in 2022:
US $ 13.90 Bn.


Forecast Period 2023 to 2029 CAGR:
10.7%
Market Size in 2029:
US $ 28.33 Bn.


 Segments Covered:
by Treatment Type
Anti-VEGF Drugs
Corticosteroid Drugs
Pan Retinal Photocoagulation Therapy
Laser Therapy


by Type
Central Retinal Vein Occlusion
Branch Retinal Vein Occlusion


by Condition
Non-Ischemic
Ischemic



Retinal Vein Occlusion Market, by Region
North America (United States, Canada and Mexico)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe)
Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC)
Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A)
South America (Brazil, Argentina Rest of South America)
Key Player
1. Novartis AG
2. Glaxo SmithKline Plc
3. Roche Holding Limited
4. Ellex Medical Lasers
5. Bristol-Myers Squibb
6. Bayer
7. Allergen PLC
8. IRIDEX Corporation
9. Regeneron Pharmaceuticals
10.BioMedical Technologies
11.Carl Zeiss AG
12.NIDEK Co., LTD
13.Topcon Corporation
14.Lumenis
15.Annexin Pharmaceuticals AB (publ)
16.Pfizer
FAQs:
1. What is the Retinal Vein Occlusion market value in 2022?
Ans: Retinal Vein Occlusion market value in 2022 was estimated as 13.90 Billion USD.

2. What is the Retinal Vein Occlusion market growth?
Ans: The market is anticipated to grow with a CAGR of 10.7% in the forecast period and is likely to reach USD 28.33 Billion by the end of 2029.

3. Which Treatment Type segment is expected to dominate the market during the forecast period?
Ans: The anti-VEGF drugs segment is projected to lead the market growth and held major share of the global retinal vein occlusion market in 2022. Rise in prevalence and incidence of diabetes drives the segment.

4. Who are the key players in the market?
Ans: The major players are Ellex Medical Lasers, Bristol-Myers Squibb, Bayer, Allergen PLC, GlaxoSmithKline PLC, IRIDEX Corporation, Regeneron Pharmaceuticals.

5. What is the key driving factor for the growth of the market?
Ans: Patients suffering from lymphoma, Glaucoma, Myeloma, a Growing rate of atherosclerosis and diabetes, lifestyle change, a rise in prevalence of eye ailments, and scientific advancements are the major factors leading to the growth of the Retinal Vein Occlusion Market.